Several research gaps exist such as the role of intravenous iron repletion in HF with preserved ejection fraction and the impact of co-administration with sodium-glucose co-transporter-2 inhibitors.At this time, increasing evidence supports the use of intravenous iron therapy for the treatment of iron deficiency in HF.The pathophysiology of iron deficiency in HF is complex and involves a number of factors, including decreased iron absorption, increased iron loss, and decreased iron bioavailability.Iron deficiency is associated with a number of adverse outcomes in HF, including worse functional capacity, increased mortality, and increased risk of hospitalization.Iron deficiency is a common problem in people with HF, affecting approximately 50% of patients.Key Findings from the HFSA Scientific Statement Beavers, PharmD, Statement Panel Co-Chair. Furthermore, the evidence is evolving, and it is critical to stay up to date on this topic," said Craig J. It is important for the heart failure team to develop strategies to address monitoring and the logistics of optimal management. "The evidence to date outlines the need for clinicians to be aware of iron deficiency and the impact. Readers will gain insight into when, how, and in whom to consider iron repletion while also understanding research gaps and future directions. This HFSA statement aims to provide up-to-date knowledge of iron deficiency in HF and practical approaches to surveillance for and management of iron deficiency."Įvidence for iron replacement emerging through multiple trials is summarized to inform readers about how iron repletion impacts functional outcomes and hospitalization/mortality in HF. "In addition, evidence is rapidly expanding to support the role of iron repletion in improving important patient outcomes. "There has been significant evolution in our knowledge of the pathophysiology, prevalence, and prognostic implications of iron deficiency in heart failure," said Gregory D. The paper discusses why iron deficiency commonly arises in HF, how iron deficiency should be evaluated, and the wide array of iron formulations currently available.
The HFSA scientific statement provides valuable information on the diagnosis and treatment of iron deficiency in HF. Iron deficiency is associated with a number of adverse outcomes in HF, including worse functional capacity, increased mortality, and increased risk of hospitalization. Lewis, MD, is based on the latest scientific evidence. The statement, which was developed by panels of experts in the field of heart failure and iron deficiency and co-chaired by Craig J.
ROCKVILLE, Md., /PRNewswire/ - The Heart Failure Society of America (HFSA) today released a new scientific statement on iron deficiency in heart failure (HF).
0 kommentar(er)
